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ABSTRACT 
Objective: The objective of this study was to develop and validate a single HPLC method, in order to separate and assay four antihistamine drugs 
diphenhydramine, chlorpheniramine, cyproheptadine and fexofenadine in pharmaceutical forms. This method was a practical additional choice in 
quality control laboratories. 
Methods: The chromatographic conditions comprised of a classical C18-type stationary phase (150 × 4.6 mm, 5μ), with a mobile phase consisting of, 
2.5g of sodium octane sulfonic acid in a mixture of 500 ml of deionized water and 500 ml of acetonitrile, and apparent pH of 2.0 was adjusted with 
phosphoric acid. The flow rate was 1 ml/min; the detection wavelengths were at 220 nm, 230 nm, 265 nm and 254 nm for diphenhydramine, 
chlorpheniramine, cyproheptadine and fexofenadine respectively. The temperature was ambient temperature. 
Results: The method was validated for linearity with correlation coefficients very close to one, the accuracy with mean recovery values between 
95.0-105.0%, precision with relative standard deviations of the calculated concentrations less than 5.0% and specificity in the presence of 
degradation products. Then it was used successfully to separate a mixture of them and to assay these drugs in pharmaceutical forms purchased 
from Syria. 
Conclusion: The results presented in this paper showed that the developed method was simple and applicable, for the separation and 
determination of the four drugs in their pharmaceutical forms. 
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The simple diphenyl derivative diphenhydramine was the first clinically 
useful member of the ethanolamine series and serves as the prototype. 
In addition, to antihistaminic action, it is antiemetic, Antitussive, and has 
sedative properties. It is used in over-the-counter (OTC) sleep-aid 
products. The propylamine antihistamines are characterized structurally 
by an sp3 or sp2 carbon, connecting atom with a carbon chain of two 
additional carbons linking the key tertiary amino, and diaryl 
pharmacophore moieties. Those propylamines with a saturated carbon 
connecting moiety are commonly referred to as the pheniramine. 
Chlorpheniramine was chosen from this group in our study. The 
dibenzocycloheptene and dibenzocycloheptene antihistamines may be 
regarded as phenothiazine analogues in which the sulfur atom has been 
replaced by an isosteric vinyl group cyproheptadine. Cyproheptadine 
possesses both antihistamine and antiserotonin activity and is used as an 
antipruritic agent. Sedation is the most prominent side effect, and this is 
usually brief disappearing after 3 or 4 d of treatment. 
Fexofenadine is a primary oxidative metabolite of terfenadine. 
Terfenadine was developed during a search for new butyrophenone 
antipsychotic drugs, as evidenced by the presence of the N-
phenylbutanol substituent. Fexofenadine is a second-generation 
antihistamine, it is selective peripheral H1-receptor blocker that, like 
produces no clinically significant anticholinergic effects or a1-
adrenergic receptor blockade at therapeutic doses. No sedative or 
another central nervous system (CNS) effects have been reported for 
this drug, (fig. 1) [1]. 
 
 
Fig. 1: Chemical structures of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine [2] 
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The recommended analytical methods of analyzing diphenhydramine, 
chlorpheniramine, cyproheptadine, fexofenadine and their related 
substances as raw materials by the British Pharmacopeia is HPLC, with 
different conditions, especially the mobile phases, the used columns 
and other experimental parameters [2]. 
Other chromatographic methods for analyzing diphenhydramine in 
formulations, were reported in the bibliography [3-6]. 
There were also many chromatographic methods, for determining 
chlorpheniramine in pharmaceuticals, in the bibliography [7-10]. 
Several analytical methods, such as liquid chromatography have 
been reported for the determination of cyproheptadine in 
pharmaceutical formulations [11-13]. 
There were also many chromatographic methods for assaying 
fexofenadine in formulations, which have been reported in the 
bibliography [13-17]. 
Other antihistamine drugs, such as brompheniramine maleate was 
estimated by HPLC [18]. 
The previous HPLC methods used different mobile phases with 
different parameters. The majority of these methods used a classical 
elution with buffers. For this reason, we decided to propose a single 
ion pair HPLC method. This proposed method may be applied to the 
four drugs with some advantages. The use of octane sulfonic acid in 
the mobile phase, instead of buffers improves its flowability through 
the HPLC chain and reduce problems of precipitation of salts on the 
electrovans, arising from the use of buffers. This technic of elution 
using a surfactant such as an octane sulfonic acid diminish the 
pression applied on the column.  
In addition, we must update the analytical methods in a regular 
manner in quality control laboratories, in order to choose the best one. 
Therefore, the objective of this work was to develop and validate an 
additional single HPLC method, for the assay of four antihistamine 
drugs diphenhydramine, chlorpheniramine, cyproheptadine and 
fexofenadine in pharmaceutical forms. 
MATERIALS AND METHODS 
Chemicals and reagents 
Working standards of diphenhydramine, chlorpheniramine, 
cyproheptadine and fexofenadine were gifted by Ibn-Alhaytham 
Industries, Aleppo-Syria. The commercial drugs (brand name-
kartastamine (diphenhydramine 25 mg Alshahbaa Industries), 
beloramine (chlorpheniramine 4 mg Mediotech Industries), 
cyproheptadine (cyproheptadine 4 mg Asia for pharmaceutical 
industries) and fexofenadine (fexofenadine 120 mg Ibn-Alhaytham 
Industries) were purchased from Syria; one commercial formulation 
was analyzed for each active pharmaceutical ingredient. All samples, 
as received, were stored in the dark at ambient temperature and 
humidity. They were all analyzed within expiry dates. All the other 
used reagents were of HPLC grade: acetonitrile (PROLABO), 
phosphoric acid (MERCK), sodium octane sulfonic acid (TEDIA), 
Deionized Water for HPLC and syringe filters 0.45 µm. 
Instrumentation 
The HPLC instrument used was an Agilent 1260 infinity, equipped 
with a UV detector. The pH meter used was from Crison. 
Reference solutions preparation 
A precise quantity of the working standards was accurately weighed, 
then dissolved in a sufficient volume of deionized water to obtain 
the starting standard solutions: diphenhydramine 0.4 mg/ml, 
chlorpheniramine 0.4 mg/ml, cyproheptadine 0.4 mg/ml and 
fexofenadine 0.4 mg/ml. These starting standard solutions were 
used for the preparation of the linearity solutions. 
Method development and optimization of chromatographic 
conditions  
Selection of detection wavelength 
The utilized detection wavelengths were at 220 nm, 230 nm, 265 nm 
and 254 nm for diphenhydramine, chlorpheniramine, 
cyproheptadine and fexofenadine respectively. 
Column selection 
An Agilent HC-C18 (octadecylsilane) reversed phase column, 150 x 
4.6 mm 5-Micron was utilized. 
Mobile phase preparation 
The mobile phase consisting of 2.5g of sodium octane sulfonic 
acid, in a mixture of 500 ml of deionized water and 500 ml of 
acetonitrile, and apparent pH of 2.0 was adjusted with 
phosphoric acid. 
Formulation solutions preparation 
Twenty tablets of kartastamine (diphenhydramine 25 mg Alshahbaa 
Industries), were crushed and powdered, then a quantity of the 
powder containing 25 mg diphenhydramine was transferred into a 
1000 ml volumetric flask containing deionized water, the content 
was dispersed under magnetic stirring during 20 min and sonicated 
for 10 min, until the active pharmaceutical ingredient was well 
dissolved (C=0.025 mg/ml). 
Twenty tablets of beloramine (chlorpheniramine 4 mg Mediotech 
Industries) were crushed and powdered, then a quantity of the 
powder containing 8 mg diphenhydramine was transferred into a 
100 ml volumetric flask containing deionized water, the content was 
dispersed under magnetic stirring during 20 min and sonicated for 
10 min, until the active pharmaceutical ingredient was well 
dissolved (C=0.08 mg/ml). 
Twenty tablets of cyproheptadine (cyproheptadine 4 mg Asia for 
pharmaceutical industries) were crushed and powdered, then a 
quantity of the powder containing 8 mg diphenhydramine was 
transferred into a 100 ml volumetric flask containing deionized 
water, the content was dispersed under magnetic stirring during 20 
min and sonicated for 10 min, until the active pharmaceutical 
ingredient was well dissolved (C=0.08 mg/ml). 
Twenty tablets of fexofenadine (fexofenadine 120 mg Ibn-
Alhaytham Industries) were crushed and powdered, then a quantity 
of the powder containing 120 mg diphenhydramine was transferred 
into a 1000 ml volumetric flask containing deionized water, the 
content was dispersed under magnetic stirring during 20 min and 
sonicated for 10 min, until the active pharmaceutical ingredient was 
well dissolved (C=0.12 mg/ml). 
Degraded starting solutions 
The starting standard solutions prepared as mentioned above were 
standing at room temperature and sunlight for 60 d. Then, they were 
analyzed for specificity tests demonstration. 
Analytical method validation 
Method validation was performed under a variety of the 
international conference on harmonization (ICH) recommended test 
conditions [19]. 
RESULTS AND DISCUSSION 
HPLC analysis 
The chromatographic conditions comprised of a C18 reversed phase 
column, 150 x 4.6 mm 5-Micron, with a mobile phase consisting of 
2.5g of sodium octane sulfonic acid in a mixture of 500 ml of 
deionized water and 500 ml of acetonitrile, and apparent pH of 2.0 
was adjusted with phosphoric acid. 
The flow rate was 1 ml/min. The utilized detection wavelengths 
were at 220 nm, 230 nm, 265 nm and 254 nm for diphenhydramine, 
chlorpheniramine, cyproheptadine and fexofenadine respectively, 
under ambient temperature. 
The reference solutions were injected under the previous 
chromatographic conditions, the retention times were 
diphenhydramine 3.8 min, chlorpheniramine 2.7 min, 
cyproheptadine 5.5 min and fexofenadine 4.3 min. we should 
mention that the peak at 1.5 min in chlorpheniramine 
chromatogram was for the maleate (fig. 2). 
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Fig. 2: Chromatograms of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine 
 
Analytical method validation 
Linearity 
The linearity of analytical procedure: is its ability (within a given 
range) to obtain test results which are directly proportional to the 
concentration of an analyte in the sample [19]. 
The linearity was evaluated by linear regression analysis, which was 
calculated by the least square regression method. Five 
concentrations over the working range were prepared for each drug; 
this process was done three different times during three weeks 
(n=3). (fig. 3) showed the regression lines of diphenhydramine, 
chlorpheniramine, cyproheptadine and fexofenadine with the 
correlation coefficients (R²) given in table 1. All the correlation 
coefficients were very close to one, so the developed method was 
linear for analyzing the four drugs. 
Range 
The linearity was demonstrated in the interval (0.025-0.4	mg/ml) 
for diphenhydramine, (0.025-0.4 mg/ml) chlorpheniramine, (0.025-
0.4 mg/ml) cyproheptadine and (0.025-0.4 mg/ml) for fexofenadine. 
 
 
Fig. 3: Linearity lines of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine 
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Table 1: Correlation coefficients of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine 
 Diphenhydramine Chlorpheniramine Cyproheptadine Fexofenadine 
Correlation coefficientsa (R2) R² = 0.999 R² = 0.999 R² = 1 R² = 999 
Equationa y = 20157x-93.97 y = 20862x+63.23 y = 15913x-14.53 y = 1151. x+2.463 
an = 3: five concentrations over the working range, were prepared for each drug; this process was done three different times during three weeks. 
 
Accuracy 
The accuracy of an analytical procedure: expresses the closeness of 
agreement between the value which is accepted either as a 
conventional true value or an accepted reference value and the value 
found. For the quantitative approaches, at least nine determinations 
across the specified range should be obtained [19]. 
Three concentration levels (0.05, 0.1, and 0.2 mg/ml) have been 
used to study the accuracy of diphenhydramine. The results 
indicated that the individual recovery ranged from 97.99% to 
101.68%. The recovery of diphenhydramine by the proposed 
method was accepted, as the mean recovery value was 99.55 
between 95.0-105.0% with RSD value 1.92 not more than 5.0%. 
Three concentration levels also (0.05, 0.1, and 0.2 mg/ml) have been 
used to study the accuracy of chlorpheniramine. The individual 
recovery ranged from 99.12% to 101.76 %. The recovery of 
chlorpheniramine by the proposed method was accepted, as the 
mean recovery value, 100.77 was between 95.0-105.0% with RSD 
value 1.43 not more than 5.0%. 
Three concentration levels (0.05, 0.1, and 0.2 mg/ml) have been 
used to study the accuracy of cyproheptadine. The individual 
recovery of cyproheptadine ranged from 98.71% to 100.68%. The 
recovery of cyproheptadine by the proposed method was accepted, 
as the mean recovery value, 99.55 was between 95.0-105.0% with 
RSD value 1.02 not more than 5.0%. 
Finally, three concentration levels (0.05, 0.1, and 0.2 mg/ml) have 
been used to study the accuracy of fexofenadine. The individual 
recovery of fexofenadine ranged from 97.85% to 101.64%. The 
recovery of fexofenadine by the proposed method was accepted, as 
the mean recovery value, 100.25 was between 95.0-105.0% with 
RSD value 2.08 not more than 5.0% table 2. 
 
Table 2: Mean recoveries of three concentration levels solutions of the four drugs 
 Diphenhydramine Chlorpheniramine Cyproheptadine Fexofenadine 
Mean concentration level1 (0.2 mg/ml) %a 98.97±6.06 101.76±2.40 100.68±2.82 101.64±3.92 
Mean concentration level2 (0.1 mg/ml) %a 97.99±6.88 101.43±2.48 99.25±2.30 101.25±4.58 
Mean concentration level3 (0.05 mg/ml) %a 101.68±7.77 99.12±3.18 98.71±1.58 97.85±4.90 
Mean recovery % (±) SD 99.55±1.90 100.77±1.44 99.55±1.01 100.25±2.08 
RSD 1.92 1.43 1.02 2.08 
amean±SD, n = 3. 
 
Precision 
The precision of an analytical procedure: expresses the closeness of 
agreement between a series of measurements obtained from 
multiple sampling of the same homogeneous sample under the 
prescribed conditions [19]. 
Intermediate Precision: The solutions 0.1 mg/ml of 
diphenhydramine, 0.1 mg/ml of chlorpheniramine, 0.1 mg/ml of 
cyproheptadine and 0.1 mg/ml of fexofenadine have been prepared 
at three different times, by three analysts during three weeks, each 
solution was injected two times (N = 6). Relative standard deviations 
of the calculated concentrations (RSD) were given in table 3. 
The RSD of diphenhydramine was 7 %, 2.45 % for 
chlorpheniramine, 2.32% for cyproheptadine and 4.52% for 
fexofenadine (not more than 5.0 %, except for diphenhydramine 
which was 7 %). These results indicated that the intermediate 
Precision of this method was accepted for diphenhydramine, and 
was good for chlorpheniramine, cyproheptadine and fexofenadine. 
 
Table 3: Relative standard deviation of the six assays of solutions of the four drugs 








1 0.093 0.102 0.099 0.107 
2 0.094 0.102 0.098 0.107 
3 0.106 0.104 0.102 0.098 
4 0.106 0.104 0.102 0.098 
5 0.090 0.098 0.097 0.099 
6 0.097 0.098 0.097 0.099 
aMean(±)SD 0.098±0.007 0.101±0.002 0.099±0.0023 0.101±0.0046 
RSD 7.03 2.45 2.32 4.52 
an = 6. 
 
Specificity 
Specificity is the ability to assess unequivocally the analyte in the 
presence of components, which may be expected to be present. 
Typically, these might include impurities, degradants, matrix, etc [19]. 
The chromatograms of the reference solutions before degradation 
indicated no additional peaks other than those of diphenhydramine 
3.8 min, chlorpheniramine 2.7 min, cyproheptadine 5.5 min and 
fexofenadine 4.3 min and the peak at 1.5 min in chlorpheniramine 
chromatogram was for the maleate (fig. 2). 
In order to demonstrate the specificity of the method, reference 
solutions were exposed to sunlight for 60 d at room temperature. 
Then, they were recorded. 
The chromatogram of the standing reference solution of 
diphenhydramine showed many additional peaks, but they were 
Trefi et al. 
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well resolved from the peak of diphenhydramine with a significant difference in the retention time (fig. 4). 
 
 
Fig. 4: Chromatogram of the standing reference solution of diphenhydramine 
 
The chromatogram of the standing reference solution of 
chlorpheniramine showed other peaks in addition to the major one 
and the maleate peak, but they were separated from the peak of 
chlorpheniramine (fig. 5). 
 
 
Fig. 5: Chromatogram of the standing reference solution of chlorpheniramine 
 
The chromatograms of the standing reference solution of 
cyproheptadine showed several additional peaks, appeared before 
the main peak with no interference (fig. 6). 
The chromatograms of the standing reference solution of 
fexofenadine showed two additional peaks, appeared after the main 
peak. In this case, there was no separation between the main peak 
and one of the degradation peaks (fig. 7). 
As a result, this method was well specific for the assay of 
diphenhydramine, chlorpheniramine, cyproheptadine, in the presence of 
their degradation products. In order to separate the fexofenadine from 
the degradation peak, modification of this method must be applied. 
On the other hand, tests for peak homogeneity were needed by using 
diode array detection or mass spectrometry but we did not dispose 
of these techniques [19]. 
Trefi et al. 




Fig. 6: Chromatogram of the standing reference solution of cyproheptadine 
 
 
Fig. 7: Chromatogram of the standing reference solution of fexofenadine 
 
 
Fig. 8: Chromatogram of a mixture of diphenhydramine, chlorpheniramine, cyproheptadine, fexofenadine 
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Separation of diphenhydramine, chlorpheniramine, cypro-
heptadine and fexofenadine mixture 
This new chromatographic method was applied literally, to separate 
a solution contains the four drugs together as a mixture. 254 nm was 
used as a common detection wavelength. The chromatogram 
showed a complete separation without any interference between the 
peaks of diphenhydramine 3.8 min, chlorpheniramine 2.8 min, 
cyproheptadine 5.1 min and fexofenadine 4.5 min. (fig. 8). 
Pharmaceutical forms assay 
Finally, we applied our method to assay commercial tablets 
purchased from Syria, which contained the four antihistamine drugs. 
One formulation was analyzed for each drug. The data of tablets 
contents were reported in table 5. It was observed that, not all the 
formulations tested had concentrations within the specification of 
the USP Pharmacopeia, which recommended that tablets should 
contain not less than 90% and not more than 110% of the labelled 
amount of the active pharmaceutical ingredient for 
diphenhydramine, chlorpheniramine and cyproheptadine and not 
less than 95% and not more than 105% for fexofenadine [20]. 
Diphenhydramine and cyproheptadine tablets contained the active 
pharmaceutical ingredient, within the range 90-110% of the stated 
concentration with RSD not more than 5%. But chlorpheniramine 
tablets contained 88.42% of the active pharmaceutical ingredient, of 
the stated concentration with RSD 2.56% which was out of the 
specification. Fexofenadine tablets content was also out of 
specification with 90.33% of the active pharmaceutical ingredient 
with RSD 1.04%.  
Nalluri B. N et al. result of assaying diphenhydramine tablets was 
99.97±0.234 [5]. Vishal Jain et al. found 100.25% of 
chlorpheniramine in formulations [7]. Rajan V. Rele. Determination 
of fexofenadine hydrochloride in pharmaceutical dosage form By 
HPLC was accurate [17].  
The results reported herein demonstrated that the quality of tablets 
of diphenhydramine, chlorpheniramine, cyproheptadine and 
fexofenadine sold in Syria was not totally correct. 
 
Table 5: Results of tablets assay by the developed HPLC method 
FormulationName Active ingredient and potency Manufacturer name and 
country of production 
Number of tablets  Drug content % (±) SDa RSD 
Kartastamine  diphenhydramine 25 mg Alshahbaa Industries (Syria) 20 95.76 2.36 
Beloramine chlorpheniramine 4 mg Mediotech Industries (Syria) 20 88.42 2.56 
 Cyproheptadine  cyproheptadine 4 mg Asia (Syria) 20 101.81 0.31 
Fexofenadine  fexofenadine 120 mg Ibn-Alhaytham (Syria) 20 90.33 1.04 
amean%±SD, n = 3. 
 
CONCLUSION 
A simple, accurate and improved ion-pair HPLC method has been 
developed for the determination of four antihistamine drugs 
diphenhydramine, chlorpheniramine, cyproheptadine and 
fexofenadine in pharmaceutical forms. This method was utilized to 
separate a mixture of the four drugs. It was applied to assay 
commercial formulations sold in Syria. This method could be an 
additional analytical technique particularly in the quality control of 
raw materials, active pharmaceutical ingredients and 
pharmaceutical formulations. The results reported herein 
demonstrated that the quality of the analyzed formulations of 
diphenhydramine, chlorpheniramine, cyproheptadine and 
fexofenadine in sold in Syria was not totally correct. 
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